Ardelyx (ARDX) | Stock Overview & Key Data
Ardelyx Performance Comparison
Stock Range
Today's Range
Low: $5.43
High: $5.64
on August 12, 2025
52 Week Range
Low: $3.21
High: $7.18
on May 15, 2025
on September 27, 2024
All-Time High: $35.48 on December 1, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.3B
EPS
-0.24
P/E Ratio (TTM)
-30.65
Forward P/E
-74.43
P/B Ratio
8.98
PEG Ratio
-74.43
Div. Yield
N/A
ROE
-39.36%
Beta
0.680
Debt to Equity
167.99
Financial Highlights
Profitability
Gross Margin
87.30%
Operating Margin
-14.74%
Profit Margin
-14.60%
Returns and Earnings
Return on Assets (TTM)
-6.23%
Return on Equity (TTM)
-39.36%
EBITDA
$-38.1M
Net Income (TTM)
$-56.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$1.62
Quarterly Revenue Growth (YoY)
33.40%
Quarterly Earnings Growth (YoY)
33.38%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ardelyx ARDX | 1.26B Small-cap | 9.16% | 21.48% | 58.64% | 2.75% | 9.38% | -4.27% | 449.02% | -5.25% |
| Vertex VRTX | 93.98B Large-cap | 3.41% | -17.91% | -11.74% | -14.44% | -4.43% | -21.56% | 25.22% | 38.03% |
| Regeneron REGN | 59.67B Large-cap | -2.34% | -2.46% | -3.31% | -16.16% | -22.18% | -53.71% | -11.71% | -9.84% |
| Harmony Biosciences HRMY | 1.97B Small-cap | 1.52% | 2.19% | -0.50% | -6.26% | 1.84% | -0.40% | -26.08% | -3.33% |
| Cg Oncology CGON | 1.89B Small-cap | -7.39% | -3.67% | -0.83% | -10.89% | -13.88% | -27.09% | -28.78% | -28.78% |
| Celcuity CELC | 1.89B Small-cap | 16.85% | 264.07% | 368.73% | 303.38% | 281.26% | 202.48% | 398.61% | 778.25% |
Ownership & Short Interest
Insider Ownership
2.50%
Institutional Ownership
72.20%
Shares Short
28M
Short Ratio
6.06
Short % of Shares Outstanding
13.06%
Average 10-Day Volume
5M
Average 90-Day Volume
5M
Ardelyx Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ardelyx would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ARDX's 52-week high and low?
- In the last 52 weeks, Ardelyx reached a high of $7.18 (on September 27, 2024) and a low of $3.21 (on May 15, 2025).
- What is the market cap and P/E ratio for ARDX?
- Curious about Ardelyx's size and valuation? Its market capitalization stands at 1.26B. When it comes to valuation, the P/E ratio (trailing twelve months) is -30.65, and the forward P/E (looking ahead) is -74.43.
- Does ARDX pay dividends? If so, what's the yield?
- As for dividends, Ardelyx isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ardelyx's main competitors or similar companies to consider before investing?
When looking at Ardelyx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX93.98B Healthcare Biotechnology -21.56% 25.22% Regeneron
REGN59.67B Healthcare Biotechnology -53.71% -11.71% Harmony Biosciences
HRMY1.97B Healthcare Biotechnology -0.40% -26.08% Cg Oncology
CGON1.89B Healthcare Biotechnology -27.09% -28.78% Celcuity
CELC1.89B Healthcare Biotechnology 202.48% 398.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ardelyx Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ardelyx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -39.36%, the Debt to Equity ratio from the most recent quarter is 167.99, and its Gross Profit Margin stands at 87.30%.
- What is the recent revenue and earnings growth for ARDX?
- Looking at Ardelyx's growth, its revenue over the trailing twelve months (TTM) was $386M. Compared to the same quarter last year (YoY), quarterly revenue grew by 33.40%, and quarterly earnings saw a YoY growth of 33.38%.
- How much of ARDX stock is held by insiders and institutions?
- Wondering who owns Ardelyx stock? Company insiders (like executives and directors) hold about 2.50% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 72.20%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.